Alkermes’ Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid detoxification.

Vivitrol is a once-monthly, extended-release injectable medication, used to treat alcohol dependence and opioid dependence.

As measured by the number of opioid-free urine screens, Vivitrol, along with psychosocial treatment, reported prolonged efficacy and safety in a one-year, open-label extension of the six-month pivotal study.

The study also measured opioid craving, improvements in quality of life measures, self-reported opioid use and incidence of physical opioid dependence.

National Institute on Drug Abuse (NIDA) has awarded Small Business Innovation Research Program grant for the clinical development programme of Vivitrol.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now